{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:44:27Z","timestamp":1763729067671,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Data on liver issues including liver cirrhosis, hepatocellular carcinoma, and hepatic failure in renal transplant patients with HCV infection are scarce. In the present study, we conducted a large-scale population-based analysis to investigate the long-term outcomes of renal recipients with HCV infection. Propensity score matching with a ratio of 1:1 was applied. A total of 6,473renal recipients with HCV infection in case group were enrolled after PSM. Our findings showed that subjects with HCV infection in kidney transplant had significantly higher risk of hepatoma, cirrhosis, hepatic failure, and overall hepatic disease than those without HCV infection. (hepatoma: HR: 8.957; 95% CI: 5.324\u201315.069; cirrhosis: HR: 5.378; 95% CI: 4.363\u20136.631; hepatic failure: HR: 3.258; 95% CI: 2.527-4.200; overall hepatic disease: HR: 4.128; 95% CI: 3.428\u20134.971). In the present study, our findings show that renal recipients with HCV infection is significantly associated with a remarkably high risk of hepatic complications post-kidney transplantation.<\/jats:p>","DOI":"10.1038\/s41598-025-15169-4","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T19:27:48Z","timestamp":1754854068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High risk of hepatic complications in kidney transplantation with chronic hepatitis C virus infection"],"prefix":"10.1038","volume":"15","author":[{"given":"Shih-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Wen","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Kuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brain K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiang-Cheng","family":"Kung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,10]]},"reference":[{"issue":"2","key":"15169_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/ajkd.2001.21294","volume":"37","author":"S Saab","year":"2001","unstructured":"Saab, S., Martin, P., Brezina, M., Gitnick, G. & Yee, H. F. Jr. Serum Alanine aminotransferase in hepatitis c screening of patients on Hemodialysis. Am. J. Kidney Dis. 37 (2), 308\u2013315 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"15169_CR2","doi-asserted-by":"publisher","first-page":"21312","DOI":"10.1038\/srep21312","volume":"6","author":"TM Yu","year":"2016","unstructured":"Yu, T. M. et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: A nationwide population-based cohort study. Sci. Rep. 6, 21312 (2016).","journal-title":"Sci. Rep."},{"issue":"10","key":"15169_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/ajt.14895","volume":"18","author":"DA Axelrod","year":"2018","unstructured":"Axelrod, D. A. et al. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes. Am. J. Transpl. 18 (10), 2473\u20132482 (2018).","journal-title":"Am. J. Transpl."},{"issue":"6","key":"15169_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2018.11.009","volume":"73","author":"D Sawinski","year":"2019","unstructured":"Sawinski, D. et al. Mortality and kidney transplantation outcomes among hepatitis C Virus-Seropositive maintenance Dialysis patients: A retrospective cohort study. Am. J. Kidney Dis. 73 (6), 815\u2013826 (2019).","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"15169_CR5","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1681\/ASN.2016010030","volume":"27","author":"M Ladino","year":"2016","unstructured":"Ladino, M., Pedraza, F. & Roth, D. Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol. 27 (8), 2238\u20132246 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"15169_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrneph.2015.5","volume":"11","author":"JM Morales","year":"2015","unstructured":"Morales, J. M. & Fabrizi, F. Hepatitis C and its impact on renal transplantation. Nat. Rev. Nephrol. 11 (3), 172\u2013182 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"15169_CR7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1681\/ASN.2010060668","volume":"22","author":"D Roth","year":"2011","unstructured":"Roth, D. et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J. Am. Soc. Nephrol. 22, 1152\u20131160 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"15169_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1399-0012.2004.00252.x","volume":"18","author":"S Sezer","year":"2004","unstructured":"Sezer, S. et al. Renal transplantation offers a better survival in HCV infected ESRD patients. Clin. Transpl. 18, 619\u2013623 (2004).","journal-title":"Clin. Transpl."},{"key":"15169_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0272-6386(97)90345-0","volume":"29","author":"GA Knoll","year":"1997","unstructured":"Knoll, G. A., Tankersley, M. R., Lee, J. Y., Julian, B. A. & Curtis, J. J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am. J. Kidney Dis. 29, 608\u2013614 (1997).","journal-title":"Am. J. Kidney Dis."},{"key":"15169_CR10","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","volume":"53","author":"BJ Pereira","year":"1998","unstructured":"Pereira, B. J. et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int. 53, 1374\u20131381 (1998).","journal-title":"Kidney Int."},{"key":"15169_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-6143.2004.00652.x","volume":"5","author":"RD Bloom","year":"2005","unstructured":"Bloom, R. D. et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am. J. Transpl. 5, 139\u2013144 (2005).","journal-title":"Am. J. Transpl."},{"key":"15169_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/ki.2011.194","volume":"80","author":"S Baid-Agrawal","year":"2011","unstructured":"Baid-Agrawal, S. et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int. 80, 879\u2013885 (2011).","journal-title":"Kidney Int."},{"key":"15169_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","volume":"65","author":"C Legendre","year":"1998","unstructured":"Legendre, C. et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65, 667\u2013670 (1998).","journal-title":"Transplantation"},{"issue":"6","key":"15169_CR14","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","volume":"5","author":"F Fabrizi","year":"2005","unstructured":"Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transpl. 5 (6), 1452\u20131461 (2005).","journal-title":"Am. J. Transpl."},{"issue":"6","key":"15169_CR15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1681\/ASN.2010060668","volume":"22","author":"D Roth","year":"2011","unstructured":"Roth, D. et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J. Am. Soc. Nephrol. 22 (6), 1152\u20131160 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"15169_CR16","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1097\/01.ASN.0000145896.16153.43","volume":"15","author":"JP Forman","year":"2004","unstructured":"Forman, J. P., Tolkoff-Rubin, N., Pascual, M., Lin, J. & Hepatitis, C. Acute humoral rejection, and renal allograft survival. J. Am. Soc. Nephrol. 15 (12), 3249\u20133255 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"15169_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2215\/CJN.02930806","volume":"2","author":"NA Terrault","year":"2007","unstructured":"Terrault, N. A. & Adey, D. B. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin. J. Am. Soc. Nephrol. 2 (3), 563\u2013575 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"15169_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00007890-200107270-00013","volume":"72","author":"HU Meier-Kriesche","year":"2001","unstructured":"Meier-Kriesche, H. U., Ojo, A. O., Hanson, J. A. & Kaplan, B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 72, 241\u2013244 (2001).","journal-title":"Transplantation"},{"key":"15169_CR19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/00007890-199612270-00013","volume":"62","author":"KV Rao","year":"1996","unstructured":"Rao, K. V. & Ma, J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 62, 1765\u20131769 (1996).","journal-title":"Transplantation"},{"key":"15169_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/ki.1991.270","volume":"40","author":"E Ponz","year":"1991","unstructured":"Ponz, E. et al. Hepatitis C virus infection among kidney transplant recipients. Kidney Int. 40, 748\u2013751 (1991).","journal-title":"Kidney Int."},{"issue":"8988","key":"15169_CR21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S0140-6736(95)92520-1","volume":"346","author":"A Corell","year":"1995","unstructured":"Corell, A. et al. Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. Lancet 346 (8988), 1497\u20131498 (1995).","journal-title":"Lancet"},{"key":"15169_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00007890-199510000-00007","volume":"60","author":"BJG Pereira","year":"1995","unstructured":"Pereira, B. J. G., Wright, T. L., Schmid, C. H. & Levey, A. S. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60, 799\u2013805 (1995).","journal-title":"Transplantation"},{"key":"15169_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/00007890-199703270-00010","volume":"63","author":"BA Bouthot","year":"1997","unstructured":"Bouthot, B. A., Murthy, B. V. R., Schmid, C. H., Levey, A. S. & Pereira, B. J. G. Long-term follow-up of hepatitis C virus infection among organ transplant recipients. Transplantation 63, 849\u2013853 (1997).","journal-title":"Transplantation"},{"key":"15169_CR24","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/ndt\/14.10.2455","volume":"14","author":"MA Gentil","year":"1999","unstructured":"Gentil, M. A. et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol. Dial Transpl. 14, 2455\u20132460 (1999).","journal-title":"Nephrol. Dial Transpl."},{"key":"15169_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1034\/j.1399-0012.2002.1o034.x","volume":"16","author":"MK Breitenfeldt","year":"2002","unstructured":"Breitenfeldt, M. K. et al. Impact of hepatitis B and C on graft loss and mortality after kidney transplantation. Clin. Transpl. 16, 130\u2013136 (2002).","journal-title":"Clin. Transpl."},{"issue":"7","key":"15169_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1681\/ASN.V1171343","volume":"11","author":"JM Morales","year":"2000","unstructured":"Morales, J. M. & Campistol, J. M. Transplantation in the patient with hepatitis C. J. Am. Soc. Nephrol. 11 (7), 1343\u20131353 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"15169_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton, M. et al. Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (3), 649\u2013659 (2015).","journal-title":"Gastroenterology"},{"issue":"1","key":"15169_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hep.27890","volume":"62","author":"SA Alqahtani","year":"2015","unstructured":"Alqahtani, S. A. et al. Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 62 (1), 25\u201330 (2015).","journal-title":"Hepatology"},{"issue":"1","key":"15169_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","volume":"62","author":"KR Reddy","year":"2015","unstructured":"Reddy, K. R. et al. Ledipasvir and Sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (1), 79\u201386 (2015).","journal-title":"Hepatology"},{"issue":"27","key":"15169_CR30","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry, M. P. et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl. J. Med. 373 (27), 2618\u20132628 (2015).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15169-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:03:04Z","timestamp":1757347384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15169"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15169-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,10]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has received approval from the institutional review board (IRB) committee of Taichung Veterans General Hospital (approval number: SE22220A, TCVGH). The informed consent of the TriNetX database was waived by the Institutional Review Board of Taichung Veterans General Hospital (TCVGH) due to the anonymous nature of the database and its strict adherence to the guidelines stipulated by the Health Insurance Portability and Accountability Act and the General Data Protection Regulation (approval number: SE22220A, TCVGH).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"29275"}}